Director Chin gets 22,500 Biomerica (BMRA) restricted shares grant

Rhea-AI Filing Summary

Biomerica director Eric Chin reported an equity award of 22,500 shares of common stock on December 12, 2025. The grant was issued at $0 per share as restricted stock under the company’s 2024 Stock Incentive Plan. Following this award, he beneficially owns 32,500 common shares directly. The restricted stock will vest in full on the one-year anniversary of December 12, 2025, if he remains in continuous service, with potential accelerated vesting in certain events, including specified changes of control.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chin Eric

(Last) (First) (Middle)

17571 VON KARMAN AVE

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMERICA INC [ BMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	12/12/2025		A		22,500(1)	A	$0	32,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Award of restricted stock under the 2024 Stock Incentive Plan. The award of restricted stock will vest in full on the one-year anniversary of December 12, 2025, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer.

	/s/ Eric Bing Chin	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Biomerica (BMRA) director Eric Chin report in this Form 4 filing?

Biomerica director Eric Chin reported receiving an award of 22,500 shares of common stock. The shares were granted as restricted stock at $0 per share and increase his directly held beneficial ownership to 32,500 shares, subject to vesting conditions described in the award terms.

How many Biomerica (BMRA) shares were granted to Eric Chin on December 12, 2025?

Eric Chin was granted 22,500 shares of Biomerica common stock on December 12, 2025. The filing classifies this as an acquisition of restricted stock at $0 per share, increasing his beneficial holdings to a total of 32,500 common shares after the transaction.

What are the vesting terms of Eric Chin’s 2025 Biomerica restricted stock award?

The restricted stock award will vest in full on the one-year anniversary of December 12, 2025. Vesting requires that Eric Chin remain in continuous service through that date, with the possibility of accelerated vesting upon certain events, including specified changes of control of Biomerica.

Under which plan was Eric Chin’s Biomerica restricted stock granted?

Eric Chin’s restricted stock was granted under Biomerica’s 2024 Stock Incentive Plan. The plan provided for the award of 22,500 shares of common stock as restricted stock, subject to time-based vesting and potential acceleration in certain circumstances outlined in the award terms.

What is Eric Chin’s Biomerica (BMRA) share ownership after this reported award?

After the reported award, Eric Chin beneficially owns 32,500 shares of Biomerica common stock. The Form 4 indicates these shares are held directly, reflecting the addition of 22,500 restricted shares granted on December 12, 2025 to his prior holdings.

Was there any cash paid for Eric Chin’s Biomerica restricted stock grant?

No cash was paid for the grant; the restricted stock was issued at $0 per share. The Form 4 shows a transaction price of $0.0000 for the 22,500 acquired shares, consistent with an equity compensation award rather than an open-market purchase.